Released Nov 14, 2013, after the close
10-Q filed Nov 14, 2013, 45 days after period end · 0001213900-13-006510
Q3 2013 · 10-Q
Revenue$6.04M$6.04M −39.0% vs Q3 2012+8.3% vs Q2 2013
Net Income-$302.08K-$302.08K N/M vs Q3 2012N/M vs Q2 2013
EPS Diluted-$0.02-$0.02 N/M vs Q3 2012N/M vs Q2 2013
Gross Profit$1,691,410−50.0%
Operating Income-$530,338N/M
Operating Cash Flowderived$1,611,728+3.8%
Free Cash Flowderived$538,076−52.8%
Margins · derived
Gross margin28.0%−6.2 pt vs Q3 2012
Operating margin-8.8%−30.8 pt vs Q3 2012
Net margin-5.0%−14.8 pt vs Q3 2012
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2013 | Q3 2012 | Q3 2011 | Q3 2010 |
|---|---|---|---|---|
| Revenue | $6.04M | $9.91M | $6.25M | $5.70M |
| Net Income | -$302.08K | $968.63K | -$1.45M | $760.16K |
| EPS Diluted | -$0.02 | $0.07 | -$0.11 | $0.10 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Tanke Biosciences Corp · CIK 1452011 · Engraved from SEC EDGAR